Cocrystal Pharma (NASDAQ: COCP) grants new stock options and bonus

Rhea-AI Filing Summary

Cocrystal Pharma is granting new non-qualified stock options to its directors, executive officers and a consultant under its 2025 Equity Incentive Plan. The options have a 10-year term, an exercise price equal to the closing price on January 8, 2026, and become effective upon execution of the company’s standard option agreement.

Half of each grant vests on January 9, 2027, with the remaining half vesting in eight equal quarterly installments starting March 31, 2027, contingent on continued service. Directors such as Dr. Roger Kornberg and Dr. Philip Frost each received 24,615 options, while James Martin and Sam Lee each received 49,229 options, and a consultant received 40,000 options. The Compensation Committee also approved a $50,000 cash award to Dr. Kornberg for his role as chairman of the Scientific Advisory Board.

false 0001412486 0001412486 2026-01-09 2026-01-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 9, 2026

Cocrystal Pharma, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-38418		35-2528215
(State or other jurisdiction		(Commission		(IRS Employer
of incorporation)		File Number)		Identification No.)

19805 N. Creek Parkway
Bothell, WA		98011
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (877) 262-7123

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		COCP		The Nasdaq Stock Market LLC (The Nasdaq Capital Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(e)

On January 9, 2026, the Compensation Committee (the “Committee”) of the Board of Directors of Cocrystal Pharma, Inc. (the “Company”) approved the grant of non-qualified stock options to the Company’s directors, executive officers and a certain consultant. The non-qualified stock options are granted under the Company’s 2025 Equity Incentive Plan, shall have a term of 10 years, be exercisable at the closing price of January 8, 2026, and the exercisability shall be subject to execution of the Company’s form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the applicable recipient continuing to serve as an officer, director or consultant of the Company, as applicable, on each applicable vesting date.

Name		For Board Service		Stock Options Granted		Stock Options Granted to Chairman and Lead Director		Total Stock Options Granted
Dr. Roger Kornberg		16,410		-		8,205		24,615
Dr. Philip Frost		16,410		-		8,205		24,615
Steve Rubin		16,410		-		-		16,410
Fred Hassan		16,410		-		-		16,410
Richard Pfenniger		16,410		-		-		16,410
Anthony Japour		16,410		-		-		16,410
James Martin		-		49,229		-		49,229
Sam Lee		-		49,229		-		49,229
Consultant		-		40,000		-		40,000

The Committee also approved a $50,000 cash award paid to Dr. Roger Kornberg for serving as chairman of the Company’s Scientific Advisory Board.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 15, 2026

	Cocrystal Pharma, Inc.
	By:	/s/ James Martin
	Name:	James Martin
	Title:	Chief Financial Officer and Co-Chief Executive Officer

FAQ

What executive compensation actions did Cocrystal Pharma (COCP) disclose?

Cocrystal Pharma disclosed that its Compensation Committee approved grants of non-qualified stock options to directors, executive officers and a consultant, plus a $50,000 cash award to Dr. Roger Kornberg.

What are the key terms of the new Cocrystal Pharma stock options?

The non-qualified stock options have a 10-year term, an exercise price set at the January 8, 2026 closing price, and are subject to execution of the company’s Non-Qualified Stock Option Agreement.

How do the Cocrystal Pharma (COCP) option grants vest?

Half of each option grant vests on January 9, 2027, and the remaining half vests in eight equal quarterly installments beginning March 31, 2027, conditioned on continued service with the company.

Which Cocrystal Pharma directors received stock option grants and in what amounts?

Directors including Dr. Roger Kornberg and Dr. Philip Frost each received 24,615 options, while Steve Rubin, Fred Hassan, Richard Pfenniger and Anthony Japour each received 16,410 options for board service.

What stock options did Cocrystal Pharma executives and a consultant receive?

James Martin and Sam Lee each received 49,229 stock options, and a consultant received 40,000 stock options under the 2025 Equity Incentive Plan.

What additional cash compensation did Cocrystal Pharma approve?

The Compensation Committee approved a $50,000 cash award to Dr. Roger Kornberg for serving as chairman of the company’s Scientific Advisory Board.